Citations

Clear

3138 citation(s) found for "Smith, AM".

Epidemiology of Uveitis in Olmsted County, Minnesota: A Population-Based Follow-Up Study
Xu, Timothy T. , Hodge, David O. , Smith, Wendy M. , Reynolds, Margaret

Mayo Clinic

Ocular Immunology and Inflammation | November 22, 2021 | Volume: 31 | Issue: 1 | Pages: 112-118

10.1080/09273948.2021.1988113 | PMID 34802369 Get It

A Policy Framework to Support Shared Decision-Making through the Use of Person-Generated Health Data
Edmunds, Margo, McGraw, Deven , Priest, Elisa L. , Smith, Jeffery, Kemp, Eagan, Campos, Hugo , Petersen, Carolyn

Mayo Clinic

ACI Open | November 16, 2021 | Volume: 05 | Issue: 02 | Pages: e104-e115

10.1055/s-0041-1736632 Get It

Abstract Background Individuals increasingly want to access, contribute to, and share their personal health information to improve outcomes, such as through shared decision-making (SDM) with their care teams. Health systems' growing capacity to use person-generated health data (PGHD) expands the opportunities for SDM. However, SDM not only lacks organizational and information infrastructure support but also is actively undermined, despite public interest in it. Objectives This work sought to identify challenges to individual–clinician SDM and policy changes needed to mitigate barriers to SDM. Methods Two multi-stakeholder group of consumers, patients, caregivers; health services researchers; and experts in health policy, informatics, social media, and user experience used a consensus process based on Bardach's policy analysis framework to identify barriers to SDM and develop recommendations to reduce these barriers. Results Technical, legal, organizational, cultural, and logistical obstacles make data sharing difficult, thereby undermining use of PGHD and realization of SDM. Stronger privacy, security, and ethical protections, including informed consent; promoting better consumer access to their data; and easier donation of personal data for research are the most crucial policy changes needed to facilitate an environment that supports SDM. Conclusion Data protection policy lags far behind the technical capacity for third parties to share and reuse electronic information without appropriate permissions, while individuals' right to access their own health information is often restricted unnecessarily, poorly understood, and poorly communicated. Sharing of personal information in a private, secure environment in which data are shared only with individuals' knowledge and consent can be achieved through policy changes.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Chang, Julie , Christian, Beth , Advani, Ranjana H. , Bartlett, Nancy L. , Vos, Sven de , Dholaria, Bhagirathbhai , Fakhri, Bita , Fayad, Luis , Glenn, Martha, Hernandez‐Ilizaliturri, Francisco J. , Kaminski, Mark , Krivacic, Susan, LaCasce, Ann S. , Narkhede, Mayur , Rabinovitch, Rachel , Roberts, Kenneth B. , Smith, Stephen D. , Svoboda, Jakub , Swinnen, Lode J., Tuscano, Joseph M. , Dwyer, Mary A., Sundar, Hema, Dholaria, Bhagirathbhai R , Bartlett, Nancy L , Advani, Ranjana H , Fakhri, Bita , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Budde, Lihua E. , Caimi, Paolo F. , Habermann, Thomas M. , Hsi, Eric D. , Hu, Boyu , Kelsey, Chris R. , Khan, Nadia , Lim, Megan S. , Ramakrishnan, Praveen , Reid, Erin G , Saeed, Hayder , Vose, Julie M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 15, 2021 | Volume: 19 | Issue: 11 | Pages: 1218-1230

10.6004/jnccn.2021.0054 | PMID 34781267 Get It

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary
Pringsheim, Tamara, Day, Gregory S. , Smith, Don B., Rae-Grant, Alex, Licking, Nicole, Armstrong, Melissa J., Bie, Rob M.A. de , Roze, Emmanuel, Miyasaki, Janis M., Hauser, Robert A. , Espay, Alberto J., Martello, Justin P., Gurwell, Julie A., Billinghurst, Lori, Sullivan, Kelly, Fitts, Michael S., Cothros, Nicholas, Hall, Deborah A., Rafferty, Miriam, Hagerbrant, Lynn, Hastings, Tara, O'Brien, Mary Dolan, Silsbee, Heather, Gronseth, Gary, Pringsheim, Tamara, Day, Gregory S., Smith, DonB., Rae-Grant, Alex, Licking, Nicole, Armstrong, Melissa J., Bie, Rob M. A. de, Roze, Emmanuel, Miyasaki, Janis M., A.Hauser, Robert, Espay, Alberto J., Martello, Justin P., Gurwell, Julie, Billinghurst, Lori, Sullivan, Kelly, Fitts, Michael S., Cothros, Nicholas, Hall, Deborah A., Rafferty, Miriam, Hagerbrant, Lynn, Hastings, Tara, O’Brien, Mary Dolan, Silsbee, Heather, Gronseth, Gary, Lang, Anthony E., Miyasaki, Janis M. , Armstrong, Melissa J. , Roze, Emmanuel , Silsbee, Heather M. , de Bie, Rob M A , Lang, Anthony E , Day, Gregory S , Hauser, Robert A , Silsbee, Heather M , Armstrong, Melissa J , Pringsheim, Tamara, Smith, Don B., Rae-Grant, Alex, Licking, Nicole, Armstrong, Melissa J., Roze, Emmanuel, Espay, Alberto J., Martello, Justin P., Gurwell, Julie A., Billinghurst, Lori, Sullivan, Kelly, Fitts, Michael S., Cothros, Nicholas, Hall, Deborah A., Rafferty, Miriam, Hagerbrant, Lynn, Hastings, Tara, O'Brien, Mary Dolan, Gronseth, Gary, Pringsheim, Tamara, Day, Gregory S., Smith, DonB., Rae-Grant, Alex, Licking, Nicole, Armstrong, Melissa J., Bie, Rob M. A. de, Miyasaki, Janis M., A.Hauser, Robert, Espay, Alberto J., Martello, Justin P., Gurwell, Julie, Billinghurst, Lori, Sullivan, Kelly, Fitts, Michael S., Cothros, Nicholas, Hall, Deborah A., Rafferty, Miriam, Hagerbrant, Lynn, Hastings, Tara, O’Brien, Mary Dolan, Silsbee, Heather, Gronseth, Gary, Lang, Anthony E.

Mayo Clinic

Neurology | November 15, 2021 | Volume: 97 | Issue: 20 | Pages: 942-957

10.1212/wnl.0000000000012868 | PMID 34782410 Get It

Introducing Exoskeletons into the Operating Room: A pilot study with vascular surgeons
Wang, Tianke , Mendes, Bernardo C. , Tetteh, Emmanuel , Smith, Tianqi Gao, Tetteh, Emmanuel , Hallbeck, M. Susan , Norasi, Hamid

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | November 12, 2021 | Volume: 65 | Issue: 1 | Pages: 1376-1380

10.1177/1071181321651212 Get It

The main goal of this pilot study was to create, implement and evaluate a strategy for introducing exoskeletons in the operating room (OR) at a quaternary care academic hospital. The strategy consisted of operating-room-specific considerations, introducing exoskeletons to surgeons, and a post-surgery survey. Three male attending vascular surgeons participated in eleven data collections to date. Low interference with surgeon’s ability to perform surgery was found for all surgical procedures, except for two open abdominal aortic procedures. The surgeons reported little to no limit on range of motion, except for one open abdominal aortic procedure. Lower than expected perceived improvement of ability to perform surgery and increase of physical comfort was self-reported. The responses indicate that the surgeons are willing to keep trying an exoskeleton intervention. In conclusion, a feasible process was created to introduce passive exoskeleton as an ergonomic intervention to vascular surgeons in their ORs.
Association of Premenopausal Bilateral Oophorectomy With Cognitive Performance and Risk of Mild Cognitive Impairment
Rocca, Walter A. , Lohse, Christine M. , Fields, Julie A. , Smith, Carin Y. , Machulda, Mary M. , Mielke, Michelle M.

Mayo Clinic

JAMA Network Open | November 11, 2021 | Volume: 4 | Issue: 11 | Pages: e2131448

10.1001/jamanetworkopen.2021.31448 | PMID 34762113 Get It

Author response: The mitochondrial iron transporter ABCB7 is required for B cell development, proliferation, and class switch recombination in mice
Lehrke, Michael Jonathan , Shapiro, Michael J. , Rajcula, Matthew, Kennedy, Madeleine M, McCue, Shaylene , Medina, Kay L. , Shapiro, Michael Jeremy, Kennedy, Madeleine, Shapiro, Virginia Smith

Mayo Clinic

No container title available | November 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.69621.sa2 Get It

Hip decompression combined with bone marrow concentrate and platelet-rich plasma for corticosteroid-induced osteonecrosis of the femoral head
Houdek, Matthew T. , Smith, John-Rudolph H. , Smith, John R. , Wyles, Cody C. , Houdek, Matthew T , Smith, John-Rudolph , Terzic, André , Behfar, Atta , Sierra, Rafael J.

Mayo Clinic

Bone & Joint Open | November 9, 2021 | Volume: 2 | Issue: 11 | Pages: 926-931

10.1302/2633-1462.211.bjo-2021-0132.r1 | PMID 34751583 Get It

Aims Bone marrow-derived mesenchymal stem cells obtained from bone marrow aspirate concentrate (BMAC) with platelet-rich plasma (PRP), has been used as an adjuvant to hip decompression. Early results have shown promise for hip preservation in patients with osteonecrosis (ON) of the femoral head. The purpose of the current study is to examine the mid-term outcome of this treatment in patients with precollapse corticosteroid-induced ON of the femoral head. Methods In all, 22 patients (35 hips; 11 males and 11 females) with precollapse corticosteroid-induced ON of the femoral head underwent hip decompression combined with BMAC and PRP. Mean age and BMI were 43 years (SD 12) and 31 kg/m² (SD 6), respectively, at the time of surgery. Survivorship free from femoral head collapse and total hip arthroplasty (THA) and risk factors for progression were evaluated at minimum five-years of clinical follow-up with a mean follow-up of seven years (5 to 8). Results Survivorship free from femoral head collapse and THA for any reason was 84% and 67% at seven years postoperatively, respectively. Risk factors for conversion to THA included a high preoperative modified Kerboul angle (grade 3 or 4) based on preoperative MRI (hazard ratio (HR) 3.96; p = 0.047) and corticosteroid use at the time of decompression (HR 4.15; p = 0.039). The seven-year survivorship for patients with grade 1 or 2 Kerboul angles for conversion to THA for articular collapse, and THA for any reason, were 96% and 72%, respectively, versus THA for articular collapse and THA for any reason in patients with grade 3 or 4 Kerboul angles of 40% (p = 0.003) and 40% (p = 0.032). Conclusion At seven years, hip decompression augmented with BMAC and PRP provided a 67% survivorship free from THA in patients with corticosteroid-induced ON. Ideal candidates for this procedure are patients with low preoperative Kerboul angles and can stop corticosteroid treatment prior to decompression. Cite this article: Bone Jt Open 2021;2(11):926–931.
Risk of hydroxychloroquine retinopathy in the community
Dabit, Jesse Y. , Hocaoǧlu, Mehmet , Moder, Kevin G., Smith, Wendy M. , O’Byrne, Thomas J., Crowson, Cynthia S. , Duarte‐García, Alí , Duarte-García, Alí , Barkmeier, Andrew J.

Mayo Clinic

Rheumatology | November 8, 2021 | Volume: 61 | Issue: 8 | Pages: 3172-3179

10.1093/rheumatology/keab844 | PMID 34788400 Get It

Abstract Objectives We aimed to estimate the risk of HCQ retinopathy and its risk factors among incident users in the community. Methods Using the Rochester Epidemiology Project, a record-linkage system, a cohort of incident users of HCQ was identified from 27 counties in the American upper Midwest. HCQ retinopathy was defined based on characteristic paracentral automated 10-2 visual field (10-2 AVF) defects and parafoveal retinal photoreceptor layer changes on spectral domain optical coherence tomography. Cumulative incidence rates were estimated adjusting for competing risk of death. Risk factors for HCQ retinopathy were examined using Cox models. Results The study included 634 incident HCQ users (mean age at initial HCQ use was 53.7 years, 79% females, 91% white). Most common indications for HCQ were RA (57%) and SLE (19%). The average follow-up length was 7.6 years. Eleven patients developed HCQ retinopathy (91% females, 91% white). The majority used HCQ for RA (91%). The cumulative incidence rate at year 5 was 0%, which increased to 3.9% (95% CI 2.0, 7.4) by 10 years. Taking an HCQ dose ≥5 mg/kg was associated with a hazard ratio (HR) of 3.59 (95% CI 1.09, 11.84) compared with lower doses. There was a 48% increase [HR 1.48 (95% CI 1.03, 2.14)] in the risk of HCQ retinopathy for each 100 g of HCQ cumulative dose. Conclusion The risk of HCQ retinopathy at 10 years of use is lower compared with previous prevalence-based estimations. A dose ≥5 mg/kg was associated with higher HCQ retinopathy risk.
The mitochondrial iron transporter ABCB7 is required for B cell development, proliferation, and class switch recombination in mice
Lehrke, Michael Jonathan , Shapiro, Michael Jeremy, Rajcula, Matthew J, Kennedy, Madeleine M, McCue, Shaylene A, Medina, Kay L, Shapiro, Virginia Smith , Shapiro, Virginia S , Lehrke, Michael J , Shapiro, Michael Jeremy, Rajcula, Matthew J, Kennedy, Madeleine M, McCue, Shaylene A, Medina, Kay L

Mayo Clinic

eLife | November 8, 2021 | Volume: 10 | Issue: No issue available | Pages: No page available

10.7554/elife.69621 | PMID 34762046 Get It

Iron-sulfur (Fe-S) clusters are cofactors essential for the activity of numerous enzymes including DNA polymerases, helicases, and glycosylases. They are synthesized in the mitochondria as Fe-S intermediates and are exported to the cytoplasm for maturation by the mitochondrial transporter ABCB7. Here, we demonstrate that ABCB7 is required for bone marrow B cell development, proliferation, and class switch recombination, but is dispensable for peripheral B cell homeostasis in mice. Conditional deletion of ABCB7 using Mb1-cre resulted in a severe block in bone marrow B cell development at the pro-B cell stage. The loss of ABCB7 did not alter expression of transcription factors required for B cell specification or commitment. While increased intracellular iron was observed in ABCB7-deficient pro-B cells, this did not lead to increased cellular or mitochondrial reactive oxygen species, ferroptosis, or apoptosis. Interestingly, loss of ABCB7 led to replication-induced DNA damage in pro-B cells, independent of VDJ recombination, and these cells had evidence of slowed DNA replication. Stimulated ABCB7-deficient splenic B cells from CD23-cre mice also had a striking loss of proliferation and a defect in class switching. Thus, ABCB7 is essential for early B cell development, proliferation, and class switch recombination.